NASDAQ:TXG 10x Genomics Q3 2026 Earnings Date & Estimates $80.65 +3.37 (+4.36%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$80.99 +0.34 (+0.42%) As of 10/9/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. 10x Genomics is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from 10x Genomics in Q3 202610x Genomics is expected to post earnings of -$0.2625 per share on revenue of $147.92 million. In the same quarter a year earlier 10x Genomics reported -$0.22 per share on revenue of $149.00 million. 10x Genomics last reported on August 6, 2026, posting -$0.14 per share and beating the -$0.2431 consensus estimate. 10x Genomics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2625Expected Revenue$147.92 millionPrior-Year EPS-$0.22Prior-Year Revenue$149.00 millionExpected Revenue Growth-0.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.14 (Beat by +$0.1031)Last Quarter Revenue$151.04 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report 10x Genomics Q3 2026 Earnings FAQ When does 10x Genomics report Q3 2026 earnings? 10x Genomics (NASDAQ:TXG) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is 10x Genomics' Q3 2026 earnings call? 10x Genomics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for 10x Genomics? Analysts expect 10x Genomics to post earnings of -$0.2625 per share for Q3 2026. How much revenue is 10x Genomics expected to report? The consensus revenue estimate for 10x Genomics is $147.92 million for Q3 2026. 10x Genomics Earnings HeadlinesWhy are 10x Genomics (TXG) shares soaring todayOctober 9 at 8:37 PM | msn.comIs 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?October 9 at 9:10 AM | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)10x Genomics Enters Research Collaboration With Fred Hutchinson Cancer CenterOctober 8 at 9:45 AM | finance.yahoo.com10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood CancersOctober 7, 2026 | prnewswire.com10x Genomics Slides as Rally Cools After Recent Product-Launch SurgeOctober 6, 2026 | quiverquant.comQSee More 10x Genomics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 10x Genomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 10x Genomics and other key companies, straight to your email. Email Address About 10x Genomics10x Genomics (NASDAQ:TXG), Inc. is a life sciences technology company that develops tools for analyzing biological systems at high resolution. Its platforms are used by academic and government research institutions, pharmaceutical and biotechnology companies, and other organizations studying genomics, cell biology, immunology, neuroscience, and disease mechanisms. The company’s product portfolio includes the Chromium platform for single-cell and other multiomics analyses, the Visium platform for spatial analysis of tissue, and the Xenium platform for high-plex in situ analysis of gene expression. These systems combine specialized instruments, consumables, assay kits, and software designed to help researchers examine genetic and molecular information while preserving details about individual cells and their locations within tissue. Founded in 2012, 10x Genomics is headquartered in Pleasanton, California, and serves customers internationally through direct sales and distribution channels. The company was co-founded by Serge Saxonov, who has served as its chief executive officer, and has built its business around expanding the use of single-cell and spatial biology technologies in research and drug discovery.View 10x Genomics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
